Ubs Group Ag Monopar Therapeutics Transaction History

Ubs Group Ag

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.31 - $1.35 $2,892 - $12,596	-9,331 Reduced 78.42%	2,568 $1,000
Q4 2023 Feb 09, 2024	BUY	$0.29 - $0.6 $3,429 - $7,096	11,827 Added 16426.39%	11,899 $4,000
Q3 2023 Nov 09, 2023	BUY	$0.57 - $1.0 $41 - $72	72 New	72 $0
Q1 2023 May 12, 2023	BUY	$1.39 - $3.73 $4,495 - $12,062	3,234 Added 102.54%	6,388 $8,000
Q4 2022 Feb 08, 2023	SELL	$2.05 - $14.95 $4,602 - $33,562	-2,245 Reduced 41.58%	3,154 $7,000
Q3 2022 Nov 10, 2022	SELL	$1.46 - $7.6 $20,676 - $107,631	-14,162 Reduced 72.4%	5,399 $8,000
Q2 2022 Aug 10, 2022	BUY	$1.85 - $2.72 $30,441 - $44,757	16,455 Added 529.78%	19,561 $45,000
Q1 2022 May 16, 2022	BUY	$2.5 - $3.62 $97 - $141	39 Added 1.27%	3,106 $8,000
Q4 2021 Feb 14, 2022	BUY	$3.17 - $5.24 $9,722 - $16,071	3,067 New	3,067 $10,000
Q2 2021 Aug 13, 2021	SELL	$5.05 - $6.49 $2,883 - $3,705	-571 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$5.76 - $10.6 $2,194 - $4,038	-381 Reduced 40.02%	571 $4,000
Q4 2020 Feb 11, 2021	BUY	$4.36 - $7.49 $4,150 - $7,130	952 New	952 $6,000
Q2 2020 Jul 31, 2020	SELL	$6.4 - $9.5 $96 - $142	-15 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$5.06 - $22.0 $6,451 - $28,050	-1,275 Reduced 98.84%	15 $0
Q4 2019 Feb 14, 2020	BUY	$16.6 - $27.0 $21,414 - $34,830	1,290 New	1,290 $21,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.